Here are seven key notes:
1. Bioventus is an orthobiologics company and BioStructures is a medical device company focused on developing bioresorbable bone graft products for spinal and orthopedic fusion procedures.
2. The agreement includes the acquisition of BioStructures’ entire portfolio of products as well as its research and development pipeline.
3. The BioStructures product portfolio includes synthetic, allograft, collagen and demineralized bone matrix solutions.
4. The company’s signature products include the Interface Bioactive Bonegraft and Signafuse Bioactive Bonegraft Putty.
5. In addition, employees of BioStructures will be given offers to join Bioventus.
6. Bioventus will continue to work with the current network of distributors carrying the BioStructures product portfolio.
7. Terms of the acquisition were not disclosed.
More articles on devices:
Less RA patients using assistive mechanical devices — 5 things to know
St. Jude Medical launches Proclaim Elite SCS System in Europe: 3 things to know
SI-BONE closes $39.2M credit facility: 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
